Physician profile
Nathan D Whitmore
NPI 1841463999
$1,483.82
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $148 · 2022: $11.71 · 2023: $233 · 2024: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444.04 | 2019-2024 | Wegovy |
| Glaxosmithkline, LLC. | $321.62 | 2019-2023 | Shingrix, Bexsero, Trelegy Ellipta |
| Lilly USA, LLC | $141.55 | 2019-2022 | |
| Astellas Pharma US INC | $124.99 | 2024 | Veozah |
| Amgen INC. | $86.51 | 2019-2020 | |
| Allergan, INC. | $62.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.89 | 2019-2020 | |
| Abbvie INC. | $47.34 | 2019-2020 | |
| Pfizer INC. | $45.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.83 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.74 | 2019 | |
| Flowonix Medical Incorporated | $23.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2019 | |
| Genentech USA, INC. | $12.50 | 2019 | |
| Sanofi Pasteur INC. | $12.22 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 | |
| Merck Sharp & Dohme LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Whitmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.